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Abstract
Current trends in patient care include the desire for minimizing invasiveness of procedures and
interventions. This aim is reflected in the increasing utilization of sentinel lymph node biopsy, which
results in a lower level of morbidity in breast cancer staging, in comparison to extensive
conventional axillary dissection. Optimized lymphoscintigraphy with triangulated body marking is a
clinical option that can further reduce morbidity, more than when a hand held gamma probe alone
is utilized. Unfortunately it is often either overlooked or not fully understood, and thus not utilized.
This results in the unnecessary loss of an opportunity to further reduce morbidity.
Optimized lymphoscintigraphy and triangulated body marking provides a detailed 3 dimensional
map of the number and location of the sentinel nodes, available before the first incision is made.
The number, location, relevance based on time/sequence of appearance of the nodes, all can
influence 1) where the incision is made, 2) how extensive the dissection is, and 3) how many nodes
are removed. In addition, complex patterns can arise from injections. These include prominent
lymphatic channels, pseudo-sentinel nodes, echelon and reverse echelon nodes and even
contamination, which are much more difficult to access with the probe only. With the detailed
information provided by optimized lymphoscintigraphy and triangulated body marking, the surgeon
can approach the axilla in a more enlightened fashion, in contrast to when the less informed probe
only method is used. This allows for better planning, resulting in the best cosmetic effect and less
trauma to the tissues, further reducing morbidity while maintaining adequate sampling of the
sentinel node(s).
Introduction
The only goal of sentinel lymph node biopsy (SLNB) is to
prevent/reduce morbidity associated with axillary lymph
node dissection (ALND) while maintaining or enhancing
sensitivity for detecting nodal disease. It has been exten-
sively demonstrated that SLNB is associated with lower
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morbidity than ALND [1-24]. Lymphoscintigraphy poten-
tially offers further reductions in morbidity, as compared
to a probe-only methodology.
Some surgeons do not utilize lymphoscintigraphy at the
time of SLNB and controversies continue [11,25-36]. One
factor that adds confusion to understanding the value of
lymphoscintigraphy is that when it is performed, there is
often wide variation in techniques and quality [37-40],
(figure 1). However, when optimized lymphoscintigraphy
with triangulated patient body marking is not performed,
an opportunity to further reduce morbidity is missed
[38,40,41], [figure 2, table 1, 2, 3]. Below is a discussion
of the advantages of lymphoscintigraphy, in which we
seek to clarify misconceptions about its utility, discuss
optimal techniques, provide an updated review of litera-
ture available on the added benefits of lymphoscintigra-
phy, and discuss its value in special situations.
Advantages of lymphoscintigraphy
Wide field of view
Optimized lymphoscintigraphy provides detailed, com-
prehensive information on sentinel node (SN) location
and on drainage routes. It has the advantage of simultane-
ously sampling the entire chest for minutes at a time, in
contrast to the probe, which samples only one particular
point for a short time [38,42-45]. Given this enhanced
global sensitivity, the camera is superior in the initial sur-
vey. In addition, the images allow identification of inter-
nal mammary and other extra axillary nodes [46-48] and
rare cases of drainage to the contralateral axilla [49-53].
When SLNB is performed in patients with previous breast
implant augmentation (where complex patterns of activ-
ity can arise), or in cases of previous SLNB, the images can
prove invaluable [54-57].
Unique drainage patterns visualized
In melanoma, lymphoscintigraphy is accepted because
globally unique drainage patterns exist. Information from
the images potentially improves staging by mapping out
drainage basins [58,59]. This advantage can be applied to
the axilla in breast cancer patients, but on a smaller, finer
scale. Even limited to the region of the axilla, lymphoscin-
tigraphy can provide similar, detailed information, as the
axilla contains multiple nodes at various levels.
Triangulated body markings improve precision
Utilizing lymphoscintigraphy, an accurate initial incision
location and dissection route can be chosen in advance.
When the patient's skin is marked with triangulation
points during lymphoscintigraphy, the surgeon can place
the incision optimally. The triangulation marks result in a
3-Dimensional pattern, which can help to direct the sur-
geon to the location of the nodes, especially in obese
patients or those with faint SNs [38,40,43], (Figure 2).
(A*) TOP: Labeled as a "typical" lymphoscintigraphy finding in  an article disputing the value of lymphoscintigraphy, the lat- eral view depicts the poor quality of injection and imaging  technique [37] Figure 1
(A*) TOP: Labeled as a "typical" lymphoscintigraphy finding in 
an article disputing the value of lymphoscintigraphy, the lat-
eral view depicts the poor quality of injection and imaging 
technique [37]. The injection site is represented by the solid 
arrow, the faint, barely visible SN by the open arrow. (B) 
BOTTOM: Right lateral view of typical/average result from 
optimized injection and imaging protocol showing injection 
sites (solid arrow) and bright sentinel node (open arrow) as 
well as lymphatic channel leading to sentinel node [38]. In 
many cases, even much brighter nodes than depicted in B are 
found. *Reprinted from Am J Surg. 177, Burak WE Jr, Routine 
preoperative lymphoscintigraphy is not necessary prior to sentinel 
node biopsy for breast cancer, 445–449., 1999, with permission 
from Elsevier Ltd.; Excerpta Medica Inc . [37].
A
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Consequently, the initial incision location and dissection
route can be better planned for the best cosmetics and
least tissue disruption. This is in contrast to an approach
using only the probe without surface markings, which
might be equivocal during the initial survey in some
patients.
Invasiveness can be further minimized
Clinical practice reveals a clear trend for minimally inva-
sive techniques and breast conservation during both ini-
tial diagnosis, staging and subsequent surgical treatment
[60-66]. The additional localizing information provided
by optimized lymphoscintigraphy will allow for fine tun-
ing of the axillary surgical approach in many patients, fur-
ther optimizing morbidity reduction.
Additional views (standing/sitting) are possible
The standing/sitting views that are possible with lympho-
scintigraphy further improve accuracy. These views reveal
adjacent nodes hidden by the injection site scatter. They
also resolve "clumping" of sentinel nodes that can occur
in the axilla in the supine patient while also eliminating
negative "end on effects" of lymphatic channels which
will be discussed below [38,43,67-69]. This is important
in delineating the true number of radioactive nodes, and
also informs the surgeons of what to expect, and how
many nodes to potentially remove [70,71]. The standing
position obviously can not be performed with the probe
at the initial survey before incision once anesthesia is
administered.
Optimizing techniques
Injection technique and Hot nodes
Injection technique is an important factor contributing to
the ease of finding the SN and the success of SLNB. Areo-
lar-cutaneous junction injections and similar injections
under the nipple increase SN activity, making the SN eas-
ier to find with the probe while generating optimal images
[38,43,72]. These injections are very efficient in delivering
activity to the SN, more so than perilesional or even intra/
sub-dermal injections [72]. This is particularly important
in the obese patient, where fat attenuates radioactivity and
also increases distances between the SN and probe. In the
setting of 15 cm of fat, less than 20% of the signal is left
after attenuation. Increased distance further weakens the
signal by 1/d2 (d = distance from probe to node) and
directionality suffers [42,73]. Gamma camera sensitivity,
conversely, does not appreciably change over distance
[73].
Augmenting activity in the SN also facilitates next day sur-
gery protocols [11,38,43,72,74-76]. Eighteen hours after
injection, the 99mTc radiotracer has decayed to where only
12.5% of the original activity remains in the SN [73]. Per-
forming injections and obtaining images using protocols
that augment SN activity on the day before surgery, will
alleviate surgical scheduling issues/delays. It can also save
operating room time, by avoiding potential delays caused
by starting the technique in the morning. These advan-
tages will result in a cost savings [74-76].
Role of blue dye
When fully optimized lymphoscintigraphy with hybrid
combination radiotracer injections is performed
[38,43,72,77], it is no longer necessary to utilize blue dye
as a primary method of finding the SN. In this setting,
blue dye serves primarily as a backup (in the rare cases
when a radioactive node is not detected) or as a secondary
method to find the SN. Dye also serves as a potential vis-
ual guide when probe directionality is occasionally poor.
Overall, dye provides less benefit than radiotracer as
noted in several studies [78-80].
An exclusively blue dye technique can be viewed as not
fully fulfilling the primary goal of morbidity reduction
that SLNB promises. It necessitates more extensive dissec-
tion, as the lymphatic ducts leading to nodes are exposed
until the SNs are found. In comparison, probe guided SN
extraction can variably detect the SN directly through tis-
sues, and further guidance is provided by lymphoscintig-
raphy images and skin markings [81-83].
Some early studies have shown 19.7% to 32.2% of SNs
detected by dye alone in patients where radiotracer was
also used [84,85]. However, these studies utilized ineffi-
cient perilesional injection techniques and no imaging
methods (probe guided only).
In contrast, King et al. used dermal injections of radiocol-
loid employing lymphoscintigraphy and perilesional
injections of dye. It was demonstrated that in 1719 proce-
dures, only 1.9% of all the SNs were blue-only, and did
not contain radioactivity detected by probe [86]. In a sub-
group of procedures where smaller volumes of dye were
used (0.1 ml–1.0 ml), only 1.3% of SNs were identified by
blue dye alone [86]. The rate of blue only SNs positive for
disease was higher however, at 10.5%. This may reflect the
lack of simultaneous perilesional and areolar radiotracer
injections as part of a hybrid injection technique as sug-
gested by our group, as only 85.8% of studies demon-
strated nodes on the images [72,86]. With experience in
using radiotracer, use of dye becomes less relevant as was
demonstrated in a study of 500 patients by Derossis et al.
where a SN identified only with dye and containing dis-
ease was seen in only 2% of cases [87].
In a recent study, Degnim et al. [88] report on 418 cases
in which radiotracer and dye were concurrently adminis-
tered for SLNB. In 380 of these, SNs were identified on the
lymphoscintigraphy images, and were recovered with theInternational Seminars in Surgical Oncology 2005, 2:25 http://www.issoonline.com/content/2/1/25
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probe and/or by visual guidance from the blue dye. In
only 3 of these 380 cases (0.79%) was disease that altered
patient staging found in a node that contained blue dye
but did not contain radioactivity [88]. In other words, had
dye not been used, disease that changed staging would
have been missed in 0.79% of total cases where SNs were
identified on lymphoscintigraphy [88]. It is possible that
technical issues, i.e., suboptimal SN intensity resulting
from using mainly perilesional and dermal over the
tumor injections, played a role in these findings. SNs were
demonstrated on lymphoscintigraphy images in only
90.9% (380/418) of total cases administered radiotracer
and dye. This is generally below the expected SN lympho-
scintigraphy visualization rate obtained with current opti-
mal areolar radiotracer injection methods and camera
imaging protocols. Optimal delivery of radiotracer to SNs
is an important issue, because the SNs involved with
tumor may have limited numbers of macrophages, which
can make the nodes appear faint if the delivery of radi-
otracer is suboptimal [38,40,72,74]. Higher efficiency are-
olar injections will generally increase activity in SNs
proportionally. This will reduce occurrences of faint, dis-
ease containing nodes that are below the threshold of
detection by the probe and camera, resulting in these
nodes being missed by these methods, but visualized with
dye. Thus, it can be postulated that even lower rates of
blue node only disease would have been found if more
efficient methods of radiotracer injection and imaging
were employed in this study. This needs to be formally
investigated.
In a study utilizing a variant of our previously reported
hybrid combination injections of dermal and perilesional
radiocolloid [77,89], without using any blue dye injec-
tions at all, Freezer et al. demonstrated a total 2% false
negative rate for SLNB in cases that received ALND who
had dynamic lymphoscintigraphy with triangulated skin
markings [90].
Lastly, King et al. [86] also reported on 143 patients
undergoing prophylactic mastectomy and SN biopsy. Of
these patients, 9.1% had occult carcinoma identified, and
the SN was positive in only 1.4% (2/143). In these partic-
ular low risk patients, the estimated probability of a blue-
only SN not containing any radioactivity that would alter
patient stage is a very small fraction of that 1.4%. Thus the
use of dye in any capacity in this limited context that may
lead to additional dissection can certainly be questioned.
Allergic/anaphylactic reactions, tattooing of skin with sur-
face injections and localized tissue inflammation have
been reported as complications to dye [86,90,91].
Examination of arguments against the use of 
lymphoscintigraphy
Several articles on lymphoscintigraphy question the value
of imaging, and report no significant difference in the
number of SNs found with and without images
[37,92,93]. However, it is important to note that both
injection and imaging techniques were key factors in these
reports. Universally, less effective perilesional injections
and non-optimized imaging techniques were utilized.
McMasters et al. reported that only 56% of patients who
had lymphoscintigraphy performed showed axillary
nodes. In addition, 36.2% showed no drainage to any
basin at all on the lymphoscintigraphy images [92]. How-
ever, these results were certainly influenced by technique.
The study was multi-center, and was performed in 1997–
1999, with only delayed views after 45–60 minutes (no
dynamic images). Only perilesional injections were uti-
lized, not the currently preferred areolar or dermal injec-
tions [92]. Considering the variation in quality of the
lymphoscintigraphy procedures performed at the differ-
ent centers, this study cannot accurately reflect what is
possible with optimized techniques of imaging, injection
and triangulated patient body marking [38,43-45,72,94-
96]. In fact, with current techniques, rates of visualization
on lymphoscintigraphy are 97%–100% [11,94-96].
In a study by Burak et al. the authors conclude that routine
preoperative lymphoscintigraphy is not necessary. How-
ever, in this study, image quality was severely compro-
mised, and sentinel nodes were noted on the images in
only 70.8% of patients. In addition to poor image quality,
this study was based on a relatively small sample size: 24
patients, (figure 1) [37]. Furthermore, imaging was per-
formed utilizing a lead shielding technique, and the
results were very poor when the tumors were in the upper
outer quadrant.
In a larger, Department of Defense study by DuPont et al.
involving 516 patients who had imaging in 1997–1999,
only 65% of patients demonstrated axillary nodes during
lymphoscintigraphy [93]. However, here technical aspects
again affected the findings. In this study, a suboptimally
narrow energy window of 10% was used as opposed to an
upwardly offset 16%–18% energy window which is rec-
ommended [38,43,73,96]. Again, only perilesional injec-
tions were used, and shielding of the injection site was
also employed. The reported methods of Burak et al. and
DuPont et al. also suggest that it is likely that suboptimal
collimators were used, along with un-optimized image
acquisition energy settings [38,43,73,96,97]. These tech-
nical shortcomings can be redressed by using high quality
cast (non-foil) collimators and optimal camera energy set-
tings, which completely obviate the need for lead shield-
ing. Lead shielding complicates lymphoscintigraphyInternational Seminars in Surgical Oncology 2005, 2:25 http://www.issoonline.com/content/2/1/25
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imaging greatly, and can lead to artifacts, missed sentinel
nodes and false nodes [38,96,97].
Clearly, these studies were influenced by significant tech-
nical limitations, as evidenced by the described methods
and/or poor quality sample images presented (figure 1).
Furthermore, suboptimal injection technique also con-
tributed to the findings, in that the more efficient injec-
tion methods (dermal or areolar) were not utilized.
Unfortunately, these articles [37,92,93] still continue to
be cited as proof of the lack of usefulness of lymphoscin-
tigraphy [98,99]. Most importantly, none of them address
the issues of potential morbidity reduction that the newer
imaging techniques provide, focusing instead mainly on
the SN detection rate or false negative rate
[37,40,41,92,93].
A new look at the literature on morbidity reduction with 
lymphoscintigraphy
Unfortunately, to date, no landmark study has been per-
formed that directly compares the additional reduction in
morbidity achieved by properly performed lymphoscin-
tigraphy, (with optimal injection technique and triangu-
lated patient body markings) vs. use of the probe alone or
dye alone. In the absence of such a study, we recently per-
formed a focused review of the literature, which indirectly
sheds light on this question [41].
Kim SC et al. [41] reviewed 20 articles addressing the dif-
ferences in morbidity between SLNB and ALND. Of these
20 articles, the authors identified 10 articles in which lym-
phoscintigraphy was used that were suitable for compari-
son to the 3 articles identified in which
lymphoscintigraphy was not utilized [41].
The percentage of patients experiencing chronic sensory
morbidity after SLNB in Kim's analysis of these articles are
depicted in Table 1. It is very important to note that mul-
tiple confounding issues may exist when comparing mor-
bidity findings among different studies. However, at the
very least, a clear trend seems to be present in Kim's anal-
ysis, which reveals that nearly twice the chronic sensory
morbidity was reported from SLNB in the articles not uti-
lizing lymphoscintigraphy but using only the probe or
using only dye, vs. those articles using both lymphoscin-
tigraphy and the probe [41], [Table 1].
Subsequent to Kim's analysis, Purushotham AD et al. [21]
reported on the results of a randomized controlled clinical
trial conducted in patients with primary breast cancer,
which sought to compare morbidity associated with SLNB
and ALND. Three hospitals participated in this study, in
which patients were randomly assigned to ALND or SLNB.
The SLNB procedure included radiotracer and blue dye.
Personal communication with authors of this study
revealed the following: in all 3 hospitals, in the SLNB arm,
in the majority of cases, lymphoscintigraphy was not per-
formed and/or if performed, was done suboptimally. In
one hospital, the use of lymphoscintigraphy was aban-
doned half way through the study due to a perceived lack
of usefulness. In another hospital lymphoscintigraphy
was not used in the vast majority of cases. In the third hos-
pital, lymphoscintigraphy was used only because it was
required by the clinical protocols of that hospital (a surgi-
cal teaching hospital), however, the imaging specialist's
reports concerning the results of lymphoscintigraphy were
not communicated to the surgeons prior to surgery [21].
In addition, at this hospital, SNs were not marked on the
patient's bodies, thus the opportunity to utilize triangu-
lated body marking, which provides surgeons with a refer-
ence for SN location in the body, was missed
[21,38,40,44,45,57].
Schematic of triangulated patient body marking technique Figure 2
Schematic of triangulated patient body marking technique. 
Different colored permanent markers are used to place ref-
erence points on the patient's body corresponding to the 
location of a sentinel node along a particular projection. 
With this form of triangulation, the location of the sentinel 
nodes can be defined in 3 dimensions along appropriate tri-
angulation lines. The arm is maintained in the surgical posi-
tion (90°) to eliminate shifting of skin markings*. The 
rotation of the torso referenced to the floor must be kept 
constant during both imaging and surgery for the relation-
ships to remain valid, or compensated for by equally shifted 
projections if rotation is desired during surgery [40]. 
*Adapted, revised and used with permission from Radiograph-
ics . 2004;24:121–145. Krynyckyi BR, et al. RSNA Publica-
tions, Oak Brook, IL. [ref. 38].
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Updated evaluation of the literature
In the vast majority of the cases in the study by Purush-
otham AD et al., lymphoscintigraphy was either used sub-
optimally or not at all [21]. Therefore, for the purposes of
comparative analysis to other studies, it can be considered
to be a non-lymphoscintigraphy study. Purushotham's
study (non lymphoscintigraphy) [21], along with three
new studies in which lymphoscintigraphy was used [22-
24], was subjected to the inclusion/exclusion criteria uti-
lized by Kim et al. [41] in their previous analysis, and the
data from these four new studies was integrated into Kim's
previous data. A new analysis of the updated dataset was
performed. The results are represented in Table 2.
This table shows that the incorporation of the new data
confirms and strengthens the trend suggested in Kim's
previous analysis [41]. The updated analysis demonstrates
over twice the chronic sensory morbidity among the stud-
ies not using lymphoscintigraphy but using probe-only or
dye-only (P < 0.0001.)
It is interesting to note that, in general, the authors of the
articles with the highest long term sensory morbidity who
did not use lymphoscintigraphy, or abandoned/dis-
counted (as shown in Table 1 and 2 above) have also pub-
lished the vast majority of articles questioning its overall
value [3,6,18,21,37,92,98-105]. This may be due to their
past experiences with lymphoscintigraphy, which have
convinced them of its lack of utility. However, it is quite
possible that the lymphoscintigraphy protocols that were
utilized in the past by these authors may have been
affected by serious technical issues (such as were
described above), resulting in suboptimal images of lim-
ited utility. Furthermore, it is likely that triangulated body
marking was not used to guide and reduce dissection and
subsequent morbidity. Based on our extensive clinical
experience, we are aware that there is clearly great varia-
tion in the quality and methods of lymphoscintigraphy
being practiced [37-40].
Intraoperative injections vs. lymphoscintigraphy
Layeeque et al. propose injecting the 99mTc sulfur colloid
intra-operatively to eliminate the pain of injection, sug-
gesting that vasovagal episodes and pain occur 10%–20%
of the time with preoperative radiotracer injections [106].
In our experience pain can be well controlled by a combi-
nation of topical anesthetic applied to the skin and the
simultaneous addition of anesthetic to the 99mTc sulfur
colloid syringe [38,43,72,77].
Layeeque et al. [106] also suggests that with intraoperative
areolar radiotracer injections, lymphoscintigraphy can be
avoided as a result of the improved efficiency of delivering
radiocolloid to the SN provided by surface injections and
by the rapid flow of tracer to the SN from the injection
site, which can reach the sentinel node before the injec-
tion is completed [38,43,72,107]. Hotter nodes are easier
to find with the probe, and there have been minor
advances in probe design, promising slightly better direc-
tionality in future models [108]. However, these superfi-
cial injection techniques are accompanied by unique
features that make the images obtained during lympho-
scintigraphy, including delayed views, all the more impor-
tant.
Performed during surgery or in the nuclear medicine
department, areolar injections will produce very promi-
nent lymphatic channels. These can complicate the
removal of nodes due to the extreme activity that can be
present in them. Immediately after areolar injection, a
very dynamic process occurs. Prominent channels appear,
often multiple, that often course a tortuous path [38,43-
45,69,72,96,107,109-111]. Nodes can blend in with
channels for over 30–120 minutes after injection. Addi-
Table 1: Comparisons of average chronic pain and numbness/paresthesia morbidity between LS groups (+) performing 
lymphoscintigraphy and non LS groups (-) not performing lymphoscintigraphy in patients undergoing SLNB using radiotracer or using 
only dye. In general, studies using lymphoscintigraphy have much lower levels of chronic sensory morbidity. Data from original 
reference by Kim SC et al. [41].
Lymphoscintigraphy (+) Performed Lymphoscintigraphy (-) Not Performed
*Morbidity (Mor) Mor (%) Total Pt (N) References Mor (%) Total Pt (N) References #p-value
Pain (>9m) 13.77% 1365 1,2,4,9,10,11,14,20 28.67% 143 6 < 0.0001
Numbness/Paresthesia (>9m) 12.56% 677 1,4,9,11,13,14,17,20 23.14% 229 3,6,18 0.0003
*Adapted, revised, and used with permission from Kim SC et al: Using the intraoperative hand held probe without lymphoscintigraphy or using only 
dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: A review of the literature. World J Surg Oncol 
2005, 3:64. [41].
#Statistics used to generate the p value: Fisher's exact test (2-tailed). A result was considered to be significant only if the p-value was lower than 
0.05.International Seminars in Surgical Oncology 2005, 2:25 http://www.issoonline.com/content/2/1/25
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tionally, channels can track superficially above the axillary
SN before coursing internally and inferiorly to the SN, in
an inverted J pattern [38,43,72]. At inflections in the
channels, activity can appear as foci, since the observer is
looking at times down/through the length of the channel
as opposed to perpendicular to it (the end on effect)
[38,43,69,77,107]. These end on effects are also noted in
all regions of the breast. Dilations/ectasias, which appear
immediately after injection, pose an additional problem
for the surgeon as they represent pseudo sentinel nodes
and can appear as distinct foci. These are much more com-
mon with the areolar injection techniques compared to
perilesional injections, as much more activity over a
shorter time period is concentrated in the lymphatic chan-
nels [38,43,72,107].
During the initial 30–120 minutes after intraoperative
injection, the surgeon is faced with a constantly changing
pattern of radioactivity. Pursuing what appear to be foci
that in fact represent end on effects or pseudo sentinel
nodes and not real nodes, can result in unnecessary dissec-
tion when using only the probe
[38,43,69,72,77,107,111]. Because these complex pat-
terns arise immediately after injection and the changes
continue over time, the information the camera provides
in the form of dynamic images, multi-angle views and
delayed views, is valuable in resolving the true nature of
the patterns, a process in which the probe is severely dis-
advantaged. In fact, intraoperative injections could actu-
ally prolong surgery and increase dissection/morbidity in
some patients, as a result of the complex post injection
dynamic patterns described above
[38,43,45,55,68,69,72,74,96,106,107,110-112]. If inter-
nal mammary sentinel nodes are deemed important to
visualize, then the use of concurrent perilesional injec-
tions as part of a hybrid injection protocol of areolar and
perilesional injections is necessary, as areolar injections
do not delineate internal mammary nodes to any extent
[38,72,113-115]. Perilesional injections require much
more time to visualize the sentinel nodes than areolar
injections.
Value of lymphoscintigraphy in special situations
There are a number of special situations in which infor-
mation provided by lymphoscintigraphy is very valuable.
These include situations of non-visualization of nodes,
training, contamination, free pertechnetate, pregnancy
and the elderly.
Even with the best areolar injection techniques, there are
rare occasions when the nodes are not seen or only appear
after an extended time period [72]. This can occur in older
patients, obese patients or those with prior lumpectomies
[43,72,77,110,116]. Knowing that the activity is weak or
absent, an additional injection can be performed employ-
ing a higher dose and/or volume of radiotracer
[40,72,112].
A final quality control check of the radiotracer occurs with
imaging. This will readily show patterns of free pertech-
netate, as well as surface contamination, which are more
difficult to detect with the probe [38,40,77].
In situations where surgeons are in the initial steps of
learning SLNB, a lack of lymphoscintigraphy images and
triangulation reference points can be detrimental to the
patient. SLNB is being performed with increasing fre-
quency, fueled by demand from patients and prevailing
trends. In the past SLNB was performed mostly by experi-
enced investigators with a strong commitment to the tech-
nique. However, with rising demand, a greater number of
less experienced mainstream surgeons are adopting SLNB
Table 2: Updated comparisons of average chronic pain and numbness/paresthesia morbidity between LS groups (+) performing 
lymphoscintigraphy and non LS groups (-) not performing lymphoscintigraphy in patients undergoing SLNB using radiotracer or using 
only dye. In general, studies using lymphoscintigraphy continue to have much lower levels of chronic sensory morbidity. Updated data 
by incorporation of four new references [21,22,23,24].
Lymphoscintigraphy (+) Performed Lymphoscintigraphy (-) Not Performed
*Morbidity (Mor) Mor (%) Total Pt (N) References Mor (%) Total Pt (N) References #p-value
Pain (>9m) 14.32% 1508 1,2,4,9,10,11,14,20,22,24 28.67% 143 6 < 0.0001
Numbness/Paresthesia (>9m) 9.22% 1052 1,4,9,11,13,14,17,20,23,24 23.17% 315 3,6,18,21t < 0.0001
*Adapted, revised, updated and used with permission from Kim SC et al: Using the intraoperative hand held probe without lymphoscintigraphy or 
using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: A review of the literature. World J 
Surg Oncol 2005, 3:64. [41].
tUse of LS is variable/suboptimal [21]. See text for details.
#Statistics used to generate the p value: Fisher's exact test (2-tailed). A result was considered to be significant only if the p-value was lower than 
0.05.International Seminars in Surgical Oncology 2005, 2:25 http://www.issoonline.com/content/2/1/25
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(in some cases reluctantly), and performing the proce-
dure. Here the lymphoscintigraphy images serve as a vital
training tool, and can support those surgeons who are
newly learning the technique of SLNB. Simulators have
been also developed that can assist, along with the
images, in training surgeons [117,118].
In pregnant women and in the elderly, SLNB is safe and
accurate [119-121]. Since time spent under anesthesia in
these patients should be minimized, knowing the number
and location of sentinel nodes and lymphatic tracts before
surgery will expedite SLNB removal, and accomplish the
goal of minimizing anesthesia time.
Limiting the numbers of nodes removed
Using lymphoscintigraphy and triangulation, Kennedy et
al. demonstrated that little benefit in additional sensitiv-
ity results from removing more than two sentinel nodes
[122]. Similarly using lymphoscintigraphy, Schrenk et al.
suggest that excising more than three nodes adds little to
accuracy [123]. Identifying which node appears first and
finding the location of the subsequent, more distant ech-
elon nodes is even more important with areolar injections
than perilesional injections. This is because areolar injec-
tions tend to delineate a greater number of echelon nodes,
as a greater percentage of the injected activity enters more
directly into the lymphatic channels and is available to
spill down over to distant echelon nodes
[38,40,43,72,74].
If faced with 6 hot nodes, it is crucial to know which
nodes are more important to excise. Only the first two to
four need to be excised if the sequence of appearance and
position along the lymphatic chain is known, especially if
both perilesional and areolar injections of radiotracer first
drain to the same primary SN. Therefore, removal of all
remote echelon nodes is probably not warranted in select
patients with a very low probability of nodal disease. Sur-
geons not utilizing lymphoscintigraphy will be faced with
several dilemmas: 1) not knowing which node was
drained to by single or combination injections, 2) not
knowing which node appeared first and second along the
lymphatic channel, 3) not knowing the relative position
of all the nodes along the lymphatic channel and 4) not
knowing their relative intensities to each other before inci-
sion. They will need to consider taking all nodes out as the
Table 3: 
Potential advantages of optimized lymphoscintigraphy 
- Reduces morbidity compared to probe only method.
- Reduces short and long term costs of treatment resulting from morbidity.
- Facilitates minimal invasiveness, improving cosmetic results.
- Assists surgeons in planning their approach and harvesting the SN.
- Provides additional guidance for surgeons who are learning the SLNB technique.
- Reduces overall surgical costs (anesthesia time, operating room utilization) by shortening surgery.
- Provides a wide field of view survey covering multiple lymph node basins simultaneously improving staging.
- Diffusion fields emanating from injection sites are defined and assessed for partly hidden nodes by scaling.
- The effects of breast displacement maneuvers are easily assessed.
- Delineates multiple SN nodes, their position and intensity along lymphatic channels, time of appearance.
- Delineates intervening nodes in unexpected positions when prominent lymphatic channels are present.
- Estimates the position of the SNs in the body from triangulated body marking (TBM).
- Surface contamination and other quality control issues are easy to detect and implement.
- Dynamic imaging is possible and its potential benefits in select cases.
- Assesses the intensity of the SN for next day surgery and determines the need for additional injections.
- Alerts to a failed node visualization (tumor replacement) and the possibility of a more extensive ALND.
- Delineates reverse echelon nodes, persistent lymphatic pools/dilations, end-on effects.
- Guides the planning of radiation ports with the inclusion of internal mammary chains when present.
- Sitting views can resolve clumped nodes, not possible with the probe after anesthesia.
- Improved localizing performance in obese patients compared to the probe before incision.
- Reduces the chance of un-harvested SNs (false negatives) through comparisons (numerical/positional/intensity) with images.
Potential disadvantages of lymphoscintigraphy 
- Additional cost of procedure.
- Technically effort-intensive to fully optimize.
- Can delay surgery if not scheduled appropriately.
- Additional patient time required and any associated discomfort during imaging.
- Inadequate reimbursement for those performing it.International Seminars in Surgical Oncology 2005, 2:25 http://www.issoonline.com/content/2/1/25
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Table 4: 
Suggested optimized lymphoscintigraphy technique 
Camera/Outlining: 
- High resolution low energy cast (non-foil) collimator [38,96,97].
- 128 × 128 matrix-dynamic, 256 × 256 matrix-static.
- Upwardly offset 99mTc energy windows and separate 57Co energy windows (122 kev) [38,43,77,96].
- Decayed 57Co sheet source transmission outlining to limit exposure [38,96].
Injection: 
- Anesthetic cream (EMLA) applied to injection sites for 30+ minutes [38,43,77].
- Hybrid radiotracer injection technique: Concurrent perilesional (2–4 ml biased away from the axilla) and areolar-cutaneous "junction" injections 
"LymphoBoost " (LB), (0.2–1.0 ml). Total dose: 150–400+ uCi 99mTc sulfur colloid for same day injections and surgery, 500–1000+ uCi for next day 
surgery. Higher LB volumes towards 1.0 ml tend to visualize nodes quicker and brighter but delineate more echelon nodes compared to lower 
volumes of 0.2 ml [38,40,43,72,74].
- High specific activity preparation, 100% filtered [130].
- Lidocain added to sulfur colloid syringe for additional pain control [38,43,77].
- Mild/short massage only [131].
- Deeper sub-lesional injections for internal mammary SN visualization if deemed important [113].
- Contamination control [77].
Acquisition sequences: 
- Optional post perilesional injection views.
- Dynamic lateral 100 frame 10 second images during areolar-cutaneous "junction" injection "LymphoBoost" (LB) [38,43,72,74].
- Optional immediate post dynamic early static sitting/standing views (see below).
- Delayed supine anterior and oblique 45° views with the arm out in the 90° surgical position and lateral views with the arm up towards the head 
with triangulated body marking of anterior and oblique 45° views.
- 57Co sheet source transmission outlining of anterior and lateral views [38,43,96].
- Sitting/Standing views highly recommended (see below).
Additional optional maneuvers: 
- Perform perilesional injection followed by 30 minute (or more) delayed views followed by LB injection (dynamic see above). Alternately delete 
perilesional injections altogether (only inject LB).
- Adaptive Injection Technique (AIT), re-inject different volumes of radiotracer based on imaging results [40],(data pending publication).
- Tape breast displacement for small breasts, for large/pendulous breasts use sitting views (see below) [38,43,96].
- Prone imaging [112], MOVA position [127], next day follow up views if two day.
- Avoid lead shielding the injection site [42,96,97].
Triangulated body marking: 
- See figure 2, [38,40,43].
Sitting/Standing views: 
- Highly recommended end of study anterior and lateral sitting/standing views with arm out in the 90° surgical position with chest pressed up 
against collimator (best resolution), two 1 minute frames each position to address motion if it occurs [38,40,43,67-71,96]. Works best in large 
breasted women.
Display: 
- Adjustment of upper level, gamma curve, pre-display low level data enhancement (pre-scale/contrast/threshold) and appropriate image summation 
[96].
- Viewing dynamic sequences in cine mode [107].
Printing: 
- Two sets of images for final supine views (marking views): with and without 57Co transmission scan (when performed) [38,96].
- Print images large enough for surgeons to clearly see anatomy. Optionally print sitting views and/or dynamic sequences if important [38,96,107].
Reporting: 
- Timely and detailed communications with surgeon before surgery to discuss findings, meaning/convention of markings and complex patterns. 
Number of SN based on supine and standing views, appearance sequence and perceived intensity, 3-D position in body, any extra-axillary or 
intramammary nodes, dilations/ectasias.International Seminars in Surgical Oncology 2005, 2:25 http://www.issoonline.com/content/2/1/25
Page 10 of 14
(page number not for citation purposes)
hottest node is not necessarily the one with disease
[124,125]. In contrast, when lymphoscintigraphy has
been performed, surgeons can approach the axilla in a
more informed fashion. Furthermore, if only a single
node is seen on the images, and clearly drained to by both
perilesional and areolar injections, then extensive dissec-
tion for additional nodes can be avoided to minimize
morbidity.
Morbidity reduction is a central goal of SLNB
When nodes are "hot", any reasonably good surgeon can
achieve good sensitivity with varying levels of dissection.
The aim is to accomplish this with as little dissection as
possible, and at the same time maintain or improve the
sensitivity. Knowing in advance the total number, loca-
tion and pattern of SNs and lymphatic channels will result
in a reduction in the total time of surgery, anesthesia,
operating room associated costs, in addition to improved
sensitivity. Most importantly a more targeted surgical
approach will result in a reduction in patient morbidity.
We observed unique patterns of drainage that can have an
impact on the false negative rate and morbidity
[38,43,50,55,69-72,74,77,96,107,113,115]. Based on the
vast experience in imaging of multiple authors as well as
ourselves [11,38,40,42-45,47,48,50,55,57,69-
72,74,77,96,107,111-115,126-129], the general tech-
niques described here form the basis of a logical algorithm
for patient management.
The fine details of optimizations for lymphoscintigraphy
are extensive and relevant mainly to the imaging special-
ist. Factors associated with optimizing the procedure
include collimator design, gamma camera energy win-
dows, radiopharmaceutical preparation, pain control,
injection location and technique, dynamic and multi-
angle camera views, patient arm and body positions, tri-
angulated body marking, breast displacement maneuvers,
outlining techniques, image display and printing parame-
ters and a thorough communication with the surgeon
regarding the findings. A condensed, referenced protocol
is presented in table 4.
Summary
SLNB has essentially become the standard of care irrespec-
tive of pending prospective data [132]. Besides the critical
questions of false negative rates, equally important
emphasis should be placed on further reducing morbidity
by optimization of sentinel node excisional techniques. In
order to accomplish this objective, SLNB methodology
should include 1) detailed, optimized lymphoscintigra-
phy, 2) maneuvers to increase activity within the SN and
3) triangulated patient body marking. At the present time,
in general, these methods are often either not used (alone
or in combination), or if they are used, are done so in a
suboptimal manner. A paradigm shift in departmental
methods is needed to incorporate these valuable tech-
niques, in order to meet the objectives of minimally inva-
sive surgery, breast conservation and morbidity reduction.
While it is may be true that all women who have SLNB do
not benefit directly from lymphoscintigraphy images, in
the patients where the images make a difference and
reduce morbidity, a very meaningful improvement in
patient care will have been achieved.
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